Therapeutical Class：Sulfonamide derivative, inhibit synthesis of dihydrofolic acid and inhibit dihydrofolate reductase

Indication：Urinary tract, GI tract, respiratory tract infection caused by G(-) or G(+) bacteria and Pneumocystis jiroveci pneumonia (PCP).

Administraton：PO:

Adults: UTI: 2 tabs or 20 ml q12h.

PCP prevention: 2 tabs or 20 ml qd or tiw.

PCP treatment: 15-20 mg TMP/kg/day in 3-4 divided doses.

Children: Mild to moderate infection: 8-12 mg TMP/kg/day in 2 divided doses. Serious infection: 20 mg TMP/kg/day in divided 4 doses.

UTI: 6-12 mg TMP/kg/day in divided 2 doses.

PCP prevention: 150 mg TMP/m2/day (max 320 mg/day) in 2 divided doses for 3 days/wk.

PCP treatment: 15-20 mg TMP/kg/day in 3-4 divided doses.

Only IV:

Adults: UTI: 8-10 mg TMP/kg/day in 2-4 divided doses.

PCP treatment: 15-20 mg TMP/kg/day in 3-4 divided doses.

Children: Serious infection: 8-12 mg TMP/kg/day in 4 divided doses.

UTI: 8-10 mg TMP/kg/day in divided 2-4 doses.

PCP treatment: 15-20 mg TMP/kg/day in 3-4 divided doses.

Renal impairment: Ccr 15-30 ml/min, half usual dose;

Ccr<15 ml/min, not recommended.

Adverse Effect：Nausea, vomiting, glossitis, rash, urticaria, thrombocytopenia, aplastic anemia, leukopenia, headache, insomnia, mental depression, hyperkalaemia, hepatotoxicity.

Contraindication：Infants <2 mon, megaloblastic anemia due to folate deficiency, prophyria, pregnancy at term and during lactation, patients with Ccr< 15 ml/min.

Pregnancy Risk：C

Supply：Bacide XE “Bacide” Tab 400mg（菌特制錠 榮民）＜00140＞